The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MBOT | +117.37% | -71.76% | -22.32% | -99% |
| S&P | +12.65% | +91.73% | +13.89% | +205% |
Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.
A weekly adventure in giving unknown companies some attention.
These five news stories have the potential to produce big moves in these stocks.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 14.3% |
| Market Cap | $91.67M | 462.9% |
| Market Cap / Employee | $4.37M | 0.0% |
| Employees | 21 | -4.5% |
| Net Income | -$3.50M | -42.0% |
| EBITDA | -$3.71M | -48.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.14M | 64.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.05M | 23.7% |
| Short Term Debt | $0.10M | -7.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -62.65% | 51.3% |
| Return On Invested Capital | -169.32% | -59.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.58M | -31.7% |
| Operating Free Cash Flow | -$2.57M | -31.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.36 | 4.90 | 8.30 | 3.02 | 26.99% |
| Price to Tangible Book Value | 2.36 | 4.90 | 8.30 | 3.02 | 26.99% |
| Enterprise Value to EBITDA | -3.18 | -4.01 | -5.54 | -16.00 | 354.92% |
| Return on Equity | -200.7% | -285.0% | -66.5% | -69.8% | -48.09% |
| Total Debt | $0.09M | $0.11M | $0.14M | $0.15M | 0.68% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
